Back | Next |
home / stock / ovid / ovid message board
Subject | By | Source | When |
---|---|---|---|
What can we expect from the | Munchy | investorshub | 09/16/2020 7:56:24 PM |
What can we expect from the | Munchy | investorshub | 09/16/2020 7:56:24 PM |
new article out today at PSN: | Nfixus | investorshub | 08/28/2020 7:24:08 PM |
new article out today at PSN: | Nfixus | investorshub | 08/28/2020 7:24:08 PM |
Im here as well.. wondering when well get | dannyzee84 | investorshub | 08/20/2020 2:11:57 PM |
Im here as well.. wondering when well get | dannyzee84 | investorshub | 08/20/2020 2:11:57 PM |
znewcar1: OVID 42% v13,2M c7.37 f54,7M R@7.5 | znewcar1 | investorshangout | 06/19/2020 1:44:02 AM |
* * $OVID Video Chart 06-18-2020 * * | ClayTrader | investorshub | 06/18/2020 8:19:32 PM |
* * $OVID Video Chart 06-18-2020 * * | ClayTrader | investorshub | 06/18/2020 8:19:32 PM |
Am I the only one making | Munchy | investorshub | 05/23/2020 1:44:52 PM |
Am I the only one making | Munchy | investorshub | 05/23/2020 1:44:52 PM |
* * $OVID Video Chart 12-17-2019 * * | ClayTrader | investorshub | 12/17/2019 9:57:52 PM |
* * $OVID Video Chart 12-17-2019 * * | ClayTrader | investorshub | 12/17/2019 9:57:52 PM |
* * $OVID Video Chart 11-29-2019 * * | ClayTrader | investorshub | 11/29/2019 7:48:36 PM |
* * $OVID Video Chart 11-29-2019 * * | ClayTrader | investorshub | 11/29/2019 7:48:36 PM |
* * $OVID Video Chart 11-27-2019 * * | ClayTrader | investorshub | 11/27/2019 11:16:34 PM |
* * $OVID Video Chart 11-27-2019 * * | ClayTrader | investorshub | 11/27/2019 11:16:34 PM |
znewcar1: OVID 19% v1,3M c3.72 f47,8M H 3.9 S3.57 | znewcar1 | investorshangout | 11/27/2019 11:02:28 PM |
OVID THERAPEUTICS (NASDAQ:OVID) PRICE TARGET AND CONSENSUS RATING | stockguard | investorshub | 11/03/2019 9:54:09 PM |
OVID THERAPEUTICS (NASDAQ:OVID) PRICE TARGET AND CONSENSUS RATING | stockguard | investorshub | 11/03/2019 9:54:09 PM |
News, Short Squeeze, Breakout and More Instantly...
Ovid Therapeutics Inc. Company Name:
OVID Stock Symbol:
NASDAQ Market:
Ovid Therapeutics Inc. Website:
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid’s Scientific Advisory Board (SAB) Neuroscientists Dr. Ja...
Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti-convulsant effects in mice, reducing the severity of status epilepticus and pr...
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily d...